Compare Repligen Corporation Common Stock (RGEN) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Snap On Incorporated — how do they compare? Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B), while Snap On Incorporated trades at $365.17 (market cap $18.80B). The key difference: Snap On Incorporated is the larger of the two by market cap, and Snap On Incorporated pays a 2.68% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Snap On Incorporated for 38 Days on average.
| RGEN | SNA | |
|---|---|---|
Market Cap | $11.31B | $18.80B |
Volume | 1,216,919 | 214,829 |
Sector | Health | Industrials |
52-Week High | $194.57 | $419.31 |
52-Week Low | $102.87 | $328.69 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $11.20B | $18.44B |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Snap-On Incorporated (SNA) trades at $363.67, up 0.46% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with a 19.6% net income margin and a 17.58% ROE. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 2026 missing. Analyst consensus is bullish with a $449 price target, though technical indicators suggest near-term caution amid institutional positioning shifts.
The outlook for SNA is supported by solid fundamentals and analyst optimism, but faces headwinds from technical bearishness and valuation risks. Upside potential exists if earnings momentum continues, while risks include execution challenges and market volatility. The stock's premium valuation requires sustained growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
